Table 3.

Comparison of the effects of PHT versus placebo on PCS scores over 1 year in prevalent and incident cases of rheumatoid arthritis^*

		PCS with PHT		PCS with placebo		Difference
		N	Mean ± SD	N	Mean ± SD	Mean ± SE	P (unadjusted)	P (adjusted)
All PHT
	Baseline	38	40.92 ± 11.72	40	39.02 ± 11.79	−1.90 ± 2.66	0.478	0.089
	Year 1	37	41.92 ± 10.82	36	36.64 ± 11.27	−5.28 ± 2.59	0.045	0.005
	Year 1: baseline (absolute change)	37	0.77 ± 10.25	35	−2.89 ± 6.38	−3.65 ± 2.03	0.076	0.488
	Year 1: baseline (% change)	37	7.00 ± 30.46	35	−5.51 ± 18.54	−12.51 ± 5.98	0.040	0.353
Estrogen alone
	Baseline	11	42.43 ± 11.80	16	35.79 ± 11.20	−6.64 ± 4.48	0.151	0.552
	Year 1	10	44.07 ± 10.37	14	30.38 ± 11.24	−13.69 ± 4.51	0.006	0.105
	Year 1: baseline (absolute change)	10	0.64 ± 7.43	14	−6.01 ± 5.66	−6.64 ± 2.67	0.021	0.086
	Year 1: baseline (% change)	10	5.66 ± 23.52	14	−16.70 ± 14.82	−22.36 ± 7.81	0.009	0.055

^*PHT = postmenopausal hormone therapy; PCS = Physical Component Score.